Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment

PHASE3CompletedINTERVENTIONAL

Enrollment

354

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

October 17, 2019

Study Completion Date

October 17, 2019

Conditions

Infertility

Interventions

DRUG

QL1012

Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU

DRUG

Gonal-f ®

Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU

Trial Locations (1)

The first Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05149924 - Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment | Biotech Hunter | Biotech Hunter